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Background. Liver metastases are common in advanced breast cancer. We sought to evaluate the role of transcatheter arterial
chemoembolization (TACE) in breast cancer patients with hepatic metastases. Methods. A retrospective review of ten patients
with breast cancer who were treated with TACE for unresectable liver metastases (1998–2008). Results. All patients, median age
46.5, had received prior systemic chemotherapies. Adriamycin was administered for 6, cisplatin/gemcitabine for 2, cisplatin for
one and oxaliplatin for one patient. Median number of TACE cycles was 4. Kaplan Meier survival analysis showed an increase in
median survival for patients who responded to treatment when compared to those who did not respond (24 vs7m o n t h s ,P = .02).
Conclusions. This is one of the largest series of breast cancer patients with liver metastases treated with TACE. It suggests that TACE
is a feasible palliative option and warrants further investigations.
1.Introduction
Liver metastases are found in approximately 50% of patients
with breast cancer during their lifetime [1]. In general,
such liver involvement indicates a disseminated disease
and portends a poor prognosis with median survival of
approximately 4 months [2–4]. However, the liver is the
only site of metastasis in 5 to 25% of breast cancer patients
[3, 5]. Liver-directed therapy may delay progression of
hepatic disease and minimally impact a patient’s quality of
life. Until recently, treatment of liver metastases has been
limited to systemic agents such as chemotherapy, hormonal
therapy, and biological therapy. In carefully selected patients,
however, locoregional therapy to control hepatic tumor
burden has also been attempted by means of resection, radio
frequency ablation or hepatic artery therapy [6–13].
Transcatheter arterial chemoembolization (TACE) is a
regional therapy that can be oﬀered to patients with
unresectable liver metastases. It delivers a high dose of
chemotherapydirectlytothelivermetastasisinanattemptto
minimize systemic side eﬀects. The chemotherapeutic eﬀect
of TACE on tumor cells is augmented by the embolization-
induced tumor ischemia of the therapy [14]. It has a proven
beneﬁcial role in the treatment of hepatocellular carcinoma
as well as hepatic metastases from colorectal cancer and
neuroendocrine tumors [15–17]. However, there is currently
a paucity of data regarding its role in the management of
metastatic breast cancer. We sought to evaluate eﬃcacy and2 International Journal of Surgical Oncology
morbidity of TACE in selected patients with unresectable
liver metastases from breast cancer.
2.MaterialsandMethods
Approval from the Institutional Review Board was obtained
foraretrospectivereviewof patients treatedbetween January
1998 and January 2008. Ten patients with a diagnosis of
breast cancer and unresectable liver metastases who were
treated with TACE were identiﬁed during this period. The
main inclusion criteria for TACE were liver-dominant tumor
burden from breast cancer as seen on CT scan, progression
on systemic chemotherapy, and good performance status.
Patientwithlimitedandindolent extrahepaticdisease,which
represented less than 10% of the disease burden and with the
disease not progressing, was included in the study. Patients
with evidence of hepatic failure such as total bilirubin greater
than 3.0mg/dL, ascites, or encephalopathy were excluded
from TACE. Patient demographics, radiological and patho-
logic data on the primary and metastatic tumors, details
regarding use of systemic chemotherapy, use of hormonal
and biological treatments, and choice of TACE agents were
sought. Morbidity of TACE procedures was examined from
documentary and laboratory evidence. Clinical notes and
electronic patient records were used to obtain follow-up and
survival information.
2.1. TACE Protocol. Prior to the start of the ﬁrst cycle of
TACE, a CT scan of the chest, abdomen and pelvis was
performed to assess baseline tumor burden. A tissue biopsy
of the hepatic lesions was obtained to conﬁrm the origin
of breast cancer, and basic laboratory values such as total
bilirubin, albumin, and prothrombin time were obtained to
assess baseline liver function.
All the procedures were performed under a well-
established protocol. In the interventional radiology suite
under local anesthesia and intravenous sedation, the right
common femoral artery was accessed. Using a standard 5
French curved catheter, an angiogram was performed to
assess hepatic vascular anatomy and to examine tumor-
associated vascularity (Figure 1). Routine use of triphasic
intravenous contrast CT scan of liver and angiography
was performed to deﬁne any anatomic vascular variants
such as accessory or replaced hepatic vessels; and these
variants were included in the treatment plan on diagnosis.
Selective catheterization of hepatic artery branches was
then performed in a coaxial manner using a 3 French
microcatheter to identify tumor blush. After conﬁrming
appropriate microcatheter position, infusion of chemother-
apy (adriamycin in 6 patients, cisplatin and gemcitabine in
2 patients, cisplatin in one patient, and oxaliplatin in one
patient) was completed. For each TACE cycle, the dose of
adriamycin ranged from 40 to 80mg/m2, cisplatin 125 to
165mg/m2, gemcitabine 1250 to 1500mg/m2, and oxali-
platin 85mg/m2. The choice of the chemotherapeutic agent
depended on prior chemotherapy regimens. Chemotherapy
was ﬁrst administered to the hepatic lobe that contained the
dominant tumor burden. In cases of bilobar involvement,
each hepatic lobe was treated separately in diﬀerent TACE
Figure 1: A selective angiogram of the superior mesenteric
artery reveals the replaced right hepatic artery. Tumor-associated
hypervascularity in the liver is demonstrated.
cycles. Following arterial chemoinfusion, embolization of
the selected arterial branch was performed to near stasis of
antegrade ﬂow. Embolization was achieved using Biospheres
(Biosphere Medical, MA, USA), Gelfoam (Pﬁzer Inc, NY,
USA), or Contour (Boston Scientiﬁc, MA, USA). All patients
were observed overnight following the procedure, and
laboratory tests were performed to assess side eﬀects such as
bone marrow suppression or liver dysfunction.
2.2. Assessment of Tumor Response. Six to eight weeks
following each TACE cycle, a contrast-enhanced CT scan
of the chest, abdomen and pelvis was obtained to assess
intrahepatic tumor response to previous TACE and extra-
hepatic disease. CT scans detailing the size and the number
of liver metastases were used to deﬁne radiological tumor
response to the previous TACE session. RECIST criteria were
used to grade the CT scan ﬁndings as progressive disease,
stable disease, partial response, or complete response [18].
Assessment of radiological tumor response was carried out
retrospectively for each patient at two time points, after
the third TACE and after the last TACE. TACE cycles were
continued whileresponse wasobserved oruntilradiographic
progression was documented.
2.3. Data Analysis. Data were entered and veriﬁed in SPSS
(version 14, Chicago, IL). Descriptive statistics were per-
formed to provide information on demographic and disease
speciﬁc variables. Kaplan-Meier survival analysis was carried
out to test the diﬀerences in survival after the start of TACE
therapy between TACE responders (stable disease, partial
or complete response) and nonresponders (progression of
disease).
3. Results
3.1. Patient and Tumor Characteristics. All patients were
female, and the median age at the time of diagnosis of liverInternational Journal of Surgical Oncology 3
(a) (b)
Figure 2: A computed topography of the abdomen shows a large hypodense hepatic metastasis before the TACE (a), which has disappeared
following the TACE (b).
metastasis was 46.5 (range 29 to 60) (Table 1). Median time
interval between diagnosis of primary breast cancer and of
liver metastasis was 20 months (range 0 to 95). Primary
tumor was treated with either lumpectomy with radiation
(n = 4) or modiﬁed radical mastectomy (n = 5). One
patientunderwentanaxillarylymphnodedissectiononlyfor
stage IV disease at presentation. Axillary lymph nodes were
positive in all patients, and either estrogen or progesterone
receptors were positive in six patients.
Multiple bilobar hepatic metastases were found in nine
patients and one large right lobe lesion was found in one
patient. The range of the largest hepatic metastasis in each
patient was 2.9 to 13.4cm in largest dimension. The hepatic
metastasis was deemed surgically unresectable in all patients.
The liver was site of metastasis in only ﬁve patients, and
the remaining ﬁve patients also had isolated bone metastasis.
External beam radiation was used to treat symptomatic bone
metastasis.
All patients received systemic chemotherapy before the
beginning of TACE therapy, and six patients underwent
hormonal therapy (tamoxifen or aromatase inhibitors). Four
patients also received trastuzumab. Systemic chemother-
apy used for primary breast cancer included cyclophos-
phamide, methotrexate, 5-ﬂuorouracil, adriamycin, cis-
platin, taxol, and/or gemcitabine. Three patients received
systemic chemotherapy for breast cancer with liver metas-
tases at presentation. The remaining seven patients received
second-line systemic chemotherapy such as taxol, navelbine,
adriamycin, gemcitabine, and/or capecitabine for the liver
metastases discovered subsequent to the diagnosis of pri-
mary breast cancer. Two patients also received autologous
bone marrow transplantation after undergoing systemic
chemotherapy for liver metastasis.
3.2. TACE Procedure. A total of 42 TACE sessions were
performed (Table 2) .T h el e n g t ho fh o s p i t a ls t a yw a so n ed a y
in all the sessions. Interval between TACE cycles was 6 to 8
weeks. Median number of TACE cycles administered was 4
(range 1 to 6).
3.3. Tumor Response and Morbidity. According to the
RECIST criteria, surveillance CT scans showed that after
the third cycle of the TACE, liver metastases progressed in
5 patients, stabilized in 3 patients, and partially responded
in 1 patient. One patient received only one cycle of TACE.
After the last cycle of the TACE, the disease progressed in 6
patients, stabilized in 2 patients, and partially responded in
2 patients (Figures 2(a) and 2(b)). Tumor markers (CA15.3,
CA125orCEA)decreasedin5patientsduringTACEtherapy.
Of note, tumor markers decreased in all four patients
who responded by radiological criteria following TACE. In
contrast, ﬁve out of six patients who progressed on CT scan
during TACE treatment also exhibited an increase in tumor
markers.
T h em o s tc o m m o ns i d ee ﬀect was postembolization
syndrome (transient abdominal pain, nausea and/or vom-
iting) (n = 7). Three patients had transient neutropenia
requiring treatment with ﬁlgrastim. Three patients had
transient elevation of liver enzymes (ALT or AST) that did
not require speciﬁc treatment.
3.4. Survival and Followup. Median time intervals from the
diagnosis of liver metastasis to death (n = 8) or last
followup (n = 2) was 26 months (range 1 to 65). Six
patients developed new or progressive extrahepatic metas-
tasis during TACE therapy. Using Kaplan Meier survival
analysis, median time interval from the ﬁrst TACE therapy
to death or last followup was 12 months (range 1 to 26,
95% conﬁdence interval = 4.9–19.1 months) (Figure 3).
Using radiological assessment of tumor response to TACE,
a statistically signiﬁcant increase in median survival was
observed for four patients who responded to treatment4 International Journal of Surgical Oncology
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Figure 3: Kaplan-Meier survival curve of ten patients treated with
TACE.
(24 months) (partial response or stable disease) when com-
pared to those six patients who did not respond to treatment
(7 months) (progression of disease) (P = .02) (Figure 4).
In addition, using Kaplan Meier survival analysis, comparing
the three diﬀerent types of chemoembolization, a statistically
signiﬁcant increase in median survival (16 months) was
observed for six patients who received adriamycin when
compared to four patients who received cisplatin and/or
gemcitabine(12 months) or oxaliplatin (1month) (P = .01).
4. Discussion
For patients with unresectable breast cancer liver metastases,
the goal of treatment is to palliate symptoms and prolong
survival without compromising the quality of remaining
l i f e .R e c e n ta d v a n c e si ns y s t e m i ct h e r a p i e ss u c ha st a x a n e s ,
aromatase inhibitors, and trastuzumab have helped to con-
tain tumor progression in patients with advanced disease.
Regional therapies such as hepatic resection have a role in
selected patients, and retrospective case series have reported
5-year survival rates of 21% to 61% after resection of breast
cancer liver metastases [6–9, 11, 12]. However, only a small
number of patients are eligible for such a therapy, and
there is therefore a need for an eﬀective therapy that delays
progression of unresectable but isolated liver metastases.
TACE can be performed with minimal disruption in
patient’s life. The length of hospital stay for all the TACE
sessions in our study was only one day, and side eﬀects
observed after each cycle of TACE were transient and
minor. Despite the ease of application and theoretical
advantage of locoregional therapy in patients with isolated
liver metastases, there have been only few reports of TACE
in the setting of metastatic breast cancer. Our study reports
ten patients treated with TACE after they had exhausted
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Figure 4: Kaplan-Meier survival curve of responders and non-
responders to TACE therapy.
all the systemic therapeutic options available. Their exten-
sive hepatic metastases excluded them from resection or
radiofrequency ablation. We observed that by radiological
and tumor marker criteria, 40% of hepatic metastases
responded to TACE. Similarly, Li et al. reported that 35.7%
of 28 breast cancer patients with liver metastases treated
with TACE using ﬂuorouracil, cisplatin, and doxorubicin
responded on follow-up CT scans [19]. In another study,
Giroux et al. showed that ﬁve out of eight metastatic
breast cancer patients had a radiological response of hepatic
metastases to cisplatin, doxorubicin, and mitomycin-based
TACE [20]. Our series and previous published data therefore
suggest that TACE may have a palliative role in delaying
progression of isolated hepatic metastases. Of note, unlike
two previous studies using triple chemotherapeutic agents,
we observed that single-agent TACE in 8 patients and two
agents in two patients stabilized or reduced the size of liver
metastasis in 40% of patients, and adriamycin-based TACE
conferred a statistically signiﬁcant survival advantage (P =
.01) when compared to cisplatin/gemcitabine or oxaliplatin-
based TACE. This raises questions regarding the beneﬁt
of using multiple chemotherapeutic drugs for TACE. In
support, Vogl et al. studied mitomycin-based single-agent
TACE for 25 patients with liver metastases from breast
cancer as a neoadjuvant therapy prior to laser-induced
thermotherapy (LITT), and they observed a radiological
response rate of 56% following TACE before LITT [21].
In addition, all four patients in our study who have
responded to TACE had radiological evidence of response
by the third TACE, and patients who did not show signs of
response by the third cycle did not respond radiographically
to further TACE. This suggests that patients who may
beneﬁt from continuing TACE therapy can be identiﬁed byInternational Journal of Surgical Oncology 7
measuring response during early cycles of TACE therapy.
This selection process can be used to limit treatment
among nonresponders. In addition, in our study, responses
by radiological and tumor marker criteria were closely
correlated, suggesting therapeutic eﬃcacy of TACE on tumor
burden in the liver. In this small series, such data should be
considered pilot data, and thus a larger series investigation is
needed.
In our study, TACE following systemic therapy for liver
metastaseswasassociatedwithmediansurvivalof26months
from the time of diagnosis of liver metastasis, and at least
20% of patients survived 5 years. This ﬁnding is superior to
that of the reported case series in which systemic therapy
alone was used for liver metastases, which was associated
with median survival of 4 to 10 months [3, 4]. Therefore,
there may be a survival advantage for patients who also
receive TACE in addition to systemic therapy for their
hepatic metastases. In support, Schneebaum et al. also found
that the median survival was 27 months for those patients
who were treated with regional therapy (either resection or
regional chemotherapy), which was signiﬁcantly longer than
the medial survival of ﬁve months for those patients who
received systemic chemotherapy alone for liver metastases
[22]. However, the median survival of 12 months from
the start of TACE in our study indicates that TACE is
clearly palliative and not a curative treatment. Six patients
developed new extrahepatic metastases during TACE cycles,
and four of them were bone metastasis. Radiation is an
eﬀective palliative treatment for symptomatic bone metas-
tases, and studies have shown that bone metastases are
not an inﬂuential factor on overall survival of patients
with metastatic disease [23]. Interestingly, median survival
from the start of TACE to death or last followup for the
responders (n = 4) was 24 months compared to 7 months
observed in non-responders (n = 6). Due to the small
number of patients in our study, no ﬁrm conclusion can be
drawn from this observation, but a statistically signiﬁcant
survival advantage was found for responders (P = .02). Our
paperthereforeprovidespreliminarydatathatlocoregionally
directed therapy to isolated liver metastases associated with
radiological response can lead to prolonged survival. This
ﬁndingwarrantsfurtherinvestigationstovalidatetheeﬃcacy
of TACE in this setting in a larger cohort of patients.
5. Conclusion
Here, we report a series of breast cancer patients with
unresectable liver metastases who were treated with TACE.
TACE was used in a patient population who had failed
the ﬁrst- and second- line systemic therapy, and it was
associated with a median survival of 26 months from the
diagnosis of liver metastases. This novel approach for breast
cancer patients with liver metastases is an adjunct to existing
systemic therapy, and it oﬀers a well-tolerated palliative
therapy in patients with historically dismal prognosis. In
view of encouraging results from our study, further prospec-
tive randomized studies are warranted to assess TACE as
a regional treatment for isolated hepatic metastases from
breast cancer.
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